

Clinical trials of Immunotherapy for renal-cell carcinoma (advanced) in all type of patients

TrialResults-center www.trialresultscenter.org

1 immunotherapy

Trial	Treatments	Patients	Trials design and methods
nivolumab vs everolimus			
CheckMate 025 , 2015 [NCT01668784] n=410/411 follow-up:	3 mg of nivolumab per kilogram of body weight intravenously every 2 weeks versus 10-mg everolimus tablet orally once daily	patients with advanced clear-cell renal-cell carcinoma for which they had received previous treatment with one or two regimens of antiangiogenic therapy	Parallel groups
nivolumab+ ipilimumab vs sunitinib			
CheckMate 214 <i>ongoing</i> [NCT02231749] n=NA follow-up:	Nivolumab 3 mg/kg combined with Ipilimumab 1 mg/kg solutions intravenously every 3 weeks for 4 doses then Nivolumab 3 mg/kg solutions intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity versus Sunitinib 50 mg capsules by mouth once daily for 4 weeks then 2 weeks off, continuously until documented disease progression, discontinuation due to toxicity	patients with previously untreated Renal Cell Cancer	

References

CheckMate 025, 2015:

Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gaurer TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, R Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 2015 Sep 25;: [26406148] [10.1056/NEJMoa1510665](https://doi.org/10.1056/NEJMoa1510665)

Escudier B, Sharma P, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Gurney H, Donskov F, CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. Eur Urol 2017;: [28262413]

CheckMate 214, 0:

2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent

therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.